Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q2 2023 · 10-Q
Revenue$11.05M$11.05M+49.4% vs Q2 2022 Net Income$559.00K$559.00KN/M vs Q2 2022 EPS Diluted$0.13$0.13N/M vs Q2 2022 Gross Profit$7,219,000+88.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived$411,000N/M Free Cash Flowderived$300,000N/M Margins · derivedGross margin65.4%+13.6 pt vs Q2 2022
Operating margin11.0%+36.9 pt vs Q2 2022
Net margin5.1%+58.3 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 9, 2023 · 40 d after period end